MedDataX Logo

Study of VYD2311 for the Prevention of COVID-19

NCT ID: NCT07298434

Last Updated: 2025-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

1770 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-31

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is being tested in adults and adolescents at least 12 years old. Participants in this study will be given a "study drug" that will be either VYD2311 or placebo.

The study drug will be given as a shot into the muscle in the participant's upper thigh or upper arm once a month with a total of 3 shots during the study.

This study will help researchers see how well VYD2311 works to prevent COVID-19 during the 90 days after the first shot. The study will also look at the safety and tolerability of VYD2311, how the study drug is processed by the body (pharmacokinetics), how the immune system reacts to the study drug (immunogenicity), and how well VYD2311 can block the virus from infecting cells (neutralization). To do these tests, your blood will be drawn at certain times during the study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

COVID COVID-19 mAb antibody COVID-19 prevention VYD2311 SARS-CoV-2 Monocloncal Antibody

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VYD2311-SD (single dose)

VYD2311 administered via IM injection on Day 1, followed by placebo injection (0.9% sodium chloride \[normal saline\]) on Day 30 and Day 60

Group Type ACTIVE_COMPARATOR

VYD2311-SD

Intervention Type DRUG

VYD2311-SD (single-dose arm): Intramuscular injection dosing on Day 1 with VYD2311 and Intramuscular injection dosing Placebo (normal saline) on Day 30 and Day 60

VYD2311-MD (multidose)

VYD2311 administered via IM injection on Day 1, Day 30, and Day 60

Group Type ACTIVE_COMPARATOR

VYD2311-MD

Intervention Type DRUG

VYD2311-MD (multi-dose): Intramuscular injection dosing on Day 1, Day 30, and Day 60 with VYD2311

Placebo

Normal saline administered by IM injection on Day 1, Day 30, and Day 60

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Intramuscular injection dosing on Day 1, Day 30, and Day 60 with Placebo (Normal Saline)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VYD2311-SD

VYD2311-SD (single-dose arm): Intramuscular injection dosing on Day 1 with VYD2311 and Intramuscular injection dosing Placebo (normal saline) on Day 30 and Day 60

Intervention Type DRUG

VYD2311-MD

VYD2311-MD (multi-dose): Intramuscular injection dosing on Day 1, Day 30, and Day 60 with VYD2311

Intervention Type DRUG

Placebo

Intramuscular injection dosing on Day 1, Day 30, and Day 60 with Placebo (Normal Saline)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Participants are eligible to be included in the study only if all the following criteria apply:

1. Is an adult aged ≥18 years or an adolescent aged 12 to \<18 years weighing at least 40 kg at the time of Screening. Note: Adolescent enrollment is allowed only if permitted by the local health authorities and local ethics committees.
2. Has uninterrupted access to a device (eg, mobile phone, tablet) enabled to receive study reminders (eg, SMS text messages). The parent/guardian of adolescent participants will receive the study reminders.
3. Provides written documentation of informed consent by signing a current IEC/IRB-approved ICF at the time of Screening. In the case of adolescents, parental informed consent and adolescent assent must also be obtained.
4. Is able to understand and comply with study requirements/procedures (if applicable, with assistance by a caregiver, surrogate, or LAR) based on the assessment of the Investigator.
5. For participants assigned female sex at birth:

1. Is not of childbearing potential, OR
2. Is of childbearing potential and practicing adequate contraception for at least 7 days before dosing on Day 1, agrees to practice adequate contraception through 6 months after any dosing, and has a negative pregnancy test result on Day 1.

Note: Pregnant participants will be eligible for enrollment after iDMC review of safety data only upon Sponsor communication to sites and only in regions permitted by local health authorities and local ethics committees. If pregnant participants are eligible for enrollment, this criterion is no longer applicable.

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

1. Prior receipt of VYD2311 or pemivibart (VYD222) within 12 months before Day 1 or plans to receive pemivibart within 90 days after Day 1.
2. Prior receipt of convalescent plasma or a mAb to SARS-CoV-2 active against currently circulating variants within 120 days before Day 1 or plans to receive convalescent plasma or an active SARS-CoV-2 mAb within 90 days after Day 1.
3. Tests positive for current SARS-CoV-2 infection by local RAT or RT-PCR on Day 1.
4. Prior known or suspected SARS-CoV-2 infection within 120 days before Day 1.
5. Exposure to someone with known or suspected SARS-CoV-2 infection in the 5 days before Day 1.
6. Is acutely ill, including symptoms suggestive of SARS-CoV-2 infection, in the opinion of the investigator or has a fever ≥38 o C (≥100.4 o F) within 3 days of Day 1.
7. Received or plans to receive a non-COVID-19 vaccine within 7 days before or after each dose of study drug.
Minimum Eligible Age

12 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Invivyd, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Invivyd Investigative Site

Long Beach, California, United States

Site Status

Inviviyd Investigative Site

San Diego, California, United States

Site Status

Invivyd Investigative Site

Orlando, Florida, United States

Site Status

Invivyd Investigative Site

Hinesville, Georgia, United States

Site Status

Invivyd Investigative Site

Melrose Park, Illinois, United States

Site Status

Invivyd Investigative Site

Lenexa, Kansas, United States

Site Status

Invivyd Investigative Site

Silver Spring, Maryland, United States

Site Status

Invivyd Investigative Site

Burlington, Massachusetts, United States

Site Status

Invivyd Investigative Site

Southfield, Michigan, United States

Site Status

Invivyd Investigative Site

Maplewood, Minnesota, United States

Site Status

Invivyd Investigative Site

Independence, Missouri, United States

Site Status

Invivyd Investigative Site

Jersey City, New Jersey, United States

Site Status

Invivyd Investigative Site

The Bronx, New York, United States

Site Status

Invivyd Investigative Site

Philadelphia, Pennsylvania, United States

Site Status

Invivyd Investigative Site

Myrtle Beach, South Carolina, United States

Site Status

Invivyd Investigative Site

Goodlettsville, Tennessee, United States

Site Status

Invivyd Investigative Site

Houston, Texas, United States

Site Status

Invivyd Investigative Site

Houston, Texas, United States

Site Status

Invivyd Investigative Site

Irving, Texas, United States

Site Status

Invivyd Investigative Site

Sugar Land, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Study Inquiry

Role: CONTACT

Phone: +1 781-819-0080

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Declaration

Role: primary

Declaration

Role: primary

Study Inquiry

Role: primary

Declaration

Role: primary

Declaration

Role: primary

Declaration

Role: primary

Declaration

Role: primary

Declaration

Role: primary

Declaration

Role: primary

Declaration

Role: primary

Declaration

Role: primary

Declaration

Role: primary

Declaration

Role: primary

Declaration

Role: primary

Declaration

Role: primary

Declaration

Role: primary

Role: primary

Declaration

Role: primary

Declaration

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VYD2311-PREV-002

Identifier Type: -

Identifier Source: org_study_id